Correspondence 0001193125-24-269995 from Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc.
Date: Dec. 3, 2024 · CIK: 0001806952 · Accession: 0001193125-24-269995
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283533
Letter
VIA EDGAR Division of Corporation Finance Office of Manufacturing Attn: Tim Buchmiller RE: Lyell Immunopharma, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-283533
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283533) be accelerated by the Securities and Exchange Commission to 4:00 p.m. New York time on December 5, 2024, or as soon as practicable thereafter.
We request that we be notified of such effectiveness by a telephone call to Thomas W. Greenberg of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-7886 and that such effectiveness also be confirmed in writing.
Very truly yours,
Lyell Immunopharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP LYELL IMMUNOPHARMA, INC. 201 Haskins Way South San Francisco, California 94080 (650) 695-0677 December 3, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, NE Washington, D.C. 20549 Attn: Tim Buchmiller RE: Lyell Immunopharma, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-283533 Dear Mr. Buchmiller: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283533) be accelerated by the Securities and Exchange Commission to 4:00 p.m. New York time on December 5, 2024, or as soon as practicable thereafter. We request that we be notified of such effectiveness by a telephone call to Thomas W. Greenberg of Skadden, Arps, Slate, Meagher & Flom LLP at (212) 735-7886 and that such effectiveness also be confirmed in writing. Very truly yours, Lyell Immunopharma, Inc. By: /s/ Lynn Seely Lynn Seely President and Chief Executive Officer cc: Thomas W. Greenberg Skadden, Arps, Slate, Meagher & Flom LLP